UK court awards Apotex £17.5 million in Servier case
This article was originally published in Scrip
Apotexhas been awarded damages of £17.5 million from Servierin a long-running UK patent dispute over perindopril. Mr Justice Norris of the High Court's Chancery division estimated that the amount would adequately compensate Apotex for profits that it lost during a period when it was prevented by injunction from selling a generic version of Coversyl.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.